ストックスクリーナーアプリを入手
0.6008
7.71%
-0.0502
アフターアワーズ：
.60
-0.0008
-0.13%
前日終値:
$0.651
開ける：
$0.65
24時間の取引高:
370.21K
Relative Volume:
0.21
時価総額：
$9.49M
収益：
$1.84M
当期純損益:
$-17.51M
株価収益率:
-0.4338
EPS:
-1.3849
ネットキャッシュフロー:
$-17.30M
1週間 パフォーマンス:
+0.12%
1か月 パフォーマンス:
+24.36%
6か月 パフォーマンス:
-37.42%
1年 パフォーマンス:
-55.82%
1日の値動き範囲:
$0.5905
$0.665
1週間の範囲:
$0.56
$0.80
52週間の値動き範囲:
$0.37
$1.50
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.6008 | 9.67M | 1.84M | -17.51M | -17.30M | -1.3849 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-08 | 開始されました | ROTH Capital | Buy |
| 2021-07-29 | 開始されました | Aegis Capital | Buy |
| 2020-12-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2013-12-16 | 開始されました | Oppenheimer | Outperform |
Evogene Ltd (EVGN) 最新ニュース
Armistice Capital (EVGN) discloses 4.99% beneficial stake in Evogene shares - Stock Titan
Evogene chairman to address dissident shareholder issues in Aug 18 earnings call - Pluang
Evogene Chairman Joins Company Results Call on August 18 - Stock Titan
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
Evogene Ltd. (EVGN) investors lift beneficial stake to 19.35% of shares - Stock Titan
Evogene (EVGN): Director Leon Recanati buys 460,000 shares, now holds 8.6% - Stock Titan
Evogene (EVGN) director Leon Recanati buys 460,000 shares and reports option holdings - Stock Titan
Earnings Preview: Evogene to Report Financial Results Pre-market on August 18 - Moomoo
Leon Recanati Discloses Investment at Evogene Ltd. with 5.7% Stake - TradingView
Evogene (EVGN) director Leon Recanati buys 800,000 shares, lifts stake to 5.7% - Stock Titan
Evogene (EVGN) Insider Trading Activity 2026 - MarketBeat
Evogene Ltd. (EVGN) investor group boosts ownership to 15.98% - Stock Titan
Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evogene (NASDAQ: EVGN) Share Price, EVGN Stock News, EVGN Share Price & Updates - Kalkine
Evogene Ltd. (EVGN) director boosts stake with 800,000-share buy - Stock Titan
ICL and Lavie Bio leverage AI for the development of yield increasing Bio-Stimulants - AgroSpectrum India
Evogene Sets Sept. 4 AGM Amid Board Contest and VP Departure - The Globe and Mail
Evogene Ltd. Revenue Breakdown – NASDAQ:EVGN - TradingView
Evogene (Nasdaq: EVGN) faces proxy slate battle and reverse split decision - Stock Titan
Evogene Ltd (EVGN) Struggles Near Support as Selling Pressure PersistsNarrow Range Breakout - dars.gov.et
Evogene to release Q2 2026 financial results an... - Pluang
Evogene Ltd (EVGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Form 13D/A Evogene Ltd. For: 27 July By Investing.com - Investing.com South Africa
Evogene Ltd (EVGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evogene Ltd. (EVGN) holders report 17.41% stake and new ADS buys - Stock Titan
Evogene Ltd (EVGN) Balance Sheet - TradingKey
EVGN|Evogene Ltd|Price:0.542|Chg%:-0.006 - TradingKey
Evogene Ltd (EVGN) Cash Flow - TradingKey
AI is rewiring future of energy cropsOfer Haviv, CEO, Evogene (EVGN) - AgroSpectrum India
Evogene and ELEO join forces to develop next-gen oral PCSK9 drugs targeting billion-dollar cardio market - Indian Pharma Post
EVGN|Evogene Ltd|Price:0.655|Chg%:+0.119 - TradingKey
Evogene Ltd (EVGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evogene Ltd (EVGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evogene Ltd (EVGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Evogene Ltd (EVGN) Income Statement - TradingKey
Evogene Ltd. (EVGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Evogene Ltd (EVGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evogene and ELEO to develop new oral PCSK9 inhibitors - Pharmaceutical Business review -
Evogene Ltd. (EVGN) stock price, news, quote and history - Yahoo Finance UK
Evogene and Eleo collaborate to discover PCSK9 pathway inhibitors - BioWorld News
Evogene (EVGN) Q1 2026 Earnings: Wider-than-Expected Loss Amid Ongoing R&D InvestmentsEarnings Analysis - dars.gov.et
Evogene and ELEO partner on oral PCSK9 inhibitor development By Investing.com - Investing.com South Africa
Evogene & ELEO Partner on Oral PCSK9 Inhibitors - AllSci
Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors - Moomoo
Evogene and ELEO partner on oral PCSK9 inhibitor development - Investing.com
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases – Company Announcement - Financial Times
Evogene stock trades quietly as genomics group leans on cash and recent revenue growth - Ad-hoc-news.de
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases - PR Newswire
Evogene (EVGN) investors add 202K ADSs, now hold 16.81% stake - Stock Titan
Evogene Expands ATM Offering as Shareholder Activism Escalates - The Globe and Mail
EVGN (Nasdaq: EVGN) raises at-the-market ordinary share offering to $3.29M - Stock Titan
Evogene Ltd (EVGN) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):